Shares of DarioHealth Corp. (NASDAQ:DRIO - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $7.16 and traded as low as $4.82. DarioHealth shares last traded at $4.82, with a volume of 26,285 shares.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Alliance Global Partners began coverage on DarioHealth in a report on Wednesday, August 19th. They issued a "buy" rating and a $12.00 price target on the stock. TD Cowen cut their target price on shares of DarioHealth from $11.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DarioHealth in a research note on Tuesday, October 6th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $10.00.
Get Our Latest Research Report on DRIO
DarioHealth Price Performance
The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. The firm has a market capitalization of $47.24 million, a P/E ratio of -0.79 and a beta of 1.18. The company has a 50-day moving average price of $6.75 and a 200-day moving average price of $7.16.
DarioHealth (NASDAQ:DRIO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.37. The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. On average, sell-side analysts predict that DarioHealth Corp. will post -2.94 earnings per share for the current year.
Insider Activity
In related news, Director Dennis Matheis purchased 14,430 shares of DarioHealth stock in a transaction dated Thursday, July 23rd. The stock was bought at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the completion of the acquisition, the director directly owned 43,026 shares of the company's stock, valued at $298,170.18. This represents a 50.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.50% of the company's stock.
Institutional Trading of DarioHealth
A hedge fund recently bought a new stake in DarioHealth stock. Nantahala Capital Management LLC acquired a new position in shares of DarioHealth Corp. (NASDAQ:DRIO - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 610,691 shares of the company's stock, valued at approximately $4,030,561. Nantahala Capital Management LLC owned approximately 8.32% of DarioHealth as of its most recent filing with the Securities & Exchange Commission. 33.39% of the stock is currently owned by institutional investors and hedge funds.
About DarioHealth
(
Get Free Report)
DarioHealth Corp. is a digital health company that develops technology designed to help people manage chronic and behavioral health conditions. Its platform combines mobile applications, connected devices, data analytics and personalized coaching to support health-related decision-making and engagement.
The company's offerings have included tools for diabetes management, hypertension, weight management, musculoskeletal conditions and behavioral health. Products may incorporate connected glucose meters, blood-pressure monitors and other devices that transmit health information to the Dario app, where users can track data, receive insights and access educational or coaching resources.
DarioHealth primarily serves consumers through partnerships with employers, health plans, health-care providers and other organizations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DarioHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DarioHealth wasn't on the list.
While DarioHealth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
